Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression

A significant health-record analysis has indicated a potential link between the widely used joint supplement, glucosamine, and an accelerated progression of Alzheimer’s disease. The comprehensive study revealed that individuals who used glucosamine had a 25% higher likelihood of their mild cognitive impairment advancing to dementia. This finding emerges from a broad examination of health data, bringing a new dimension to the discussion around common supplements.

Further investigation through laboratory experiments provided insights into a possible biological mechanism. These experiments suggest that glucosamine might exacerbate an abnormal sugar-tagging process occurring in the brain, a process known to be associated with Alzheimer’s pathology. This biochemical pathway could explain the observed statistical association, though more research is needed to solidify this hypothesis.

Despite these findings, the researchers caution against drawing definitive conclusions about causation. They underscored that while the analysis points to a strong association, clinical trials are essential to determine whether glucosamine actively causes harm or accelerates the disease's progression. The scientific community awaits further rigorous testing to clarify these preliminary but notable observations regarding the popular supplement's potential effects on cognitive health.

What to watch: Clinical trials are anticipated to definitively assess if glucosamine causes or accelerates Alzheimer’s progression.

Editor's note: The article accurately reflects the source summary without adding unverified claims or misrepresenting the findings.

This article is AI-generated and fact-gated. Original reporting: ScienceDaily